EXPAND IT
Financiado
EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapy
Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized the treatment of advanced-stage cancers. One of the major limitations of ICB is that durable responses are observed only in a subset of patients and in...
Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized the treatment of advanced-stage cancers. One of the major limitations of ICB is that durable responses are observed only in a subset of patients and in some specific cancer types. We recently analyzed tumor biopsies from breast cancer patients collected during ICB and indeed observed only in a subset of patients that tumor-infiltrating T-cells undergo rapid expansion when exposed to ICB. We characterized the gene expression programs underlying this expansion at single-cell level and realized that - although these expanding T-cells are the main executors of therapeutic response to ICB - several key questions regarding their function remain unanswered. First, we lack accurate knowledge about where in the heterogeneous tumor microenvironment (TME) and in which metabolic niches T-cell expansion occurs. Secondly, based on their TCR sequence we cannot predict upfront which T-cells will expand (or rather act as bystander T-cells), nor can we say to which tumor antigens these expanding T-cells are directed. Thirdly, it is not known which molecular events underlie the generation of the tumor antigens regulating T-cell expansion. Fourthly, we also observed an expansion of the B-cell repertoire and were left with similar questions as for expanding T-cells. For instance, where are expanding B-cells located, how do they interact with expanding T-cells, and do they perhaps even recognize the same tumor antigens. In EXPAND IT, we will use several innovative (single-cell) technologies to provide answers to these questions. These insights will much better characterize the mechanisms driving response to ICB, but will also provide important answers on how to sensitize patients not responding to ICB. Our findings could also contribute to the discovery of high-avidity anti-tumor TCRs that can be used in novel TCR-based cellular therapies.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2022-09-29
Fecha Fin: 2027-12-31
Fecha Fin: 2027-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2021-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 3 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5